English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Combined small cell lung cancer (C-SCLC) was confirmed as a subset of small cell lung cancer (SCLC) by the WHO in 1999. C-SCLC is defined as pure SCLC combined with components of non-small cell lung cancer (NSCLC). Recent studies have reported that C-SCLC accounts for 5% to 61% of all SCLC cases, and there is a nonhomogenous survival difference between pure SCLC and C-SCLC groups (1-3). In those earlier small-sample retrospective studies, the differences in these results may be attributed to the type of specimens used, and different Original Article

Prognostic factors, treatment, and outcomes in combined small cell lung cancer: a SEER survey from 2004 to 2015